natgillin/translations-raw huggingface dataset:
Den gennemsnitlige stigning fra baseline i Genvoya-gruppen var mindre end i elvitegravir-gruppen 150 mg/cobicistat 150 mg/emtricitabin 200 mg/tenofovirdisoproxil (som fumarat) 245 mg (E/C/F/TDF) ved uge 144 (forskel -0,04; p < 0,001) 
Mean increases from baseline in the Genvoya group were smaller than in the elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir disoproxil (as fumarate) 245 mg (E/C/F/TDF) group at Week 144 (difference -0.04, p < 0.001).
Der bør udvises forsigtighed, når Genvoya og hormonale antikonceptiva administreres samtidigt. 
Caution should be exercised when co-administering Genvoya and a hormonal contraceptive.
Se indlægssedlen for yderligere oplysninger. 
Contains lactose, see leaflet for further information.
Tenofovir har aktivitet mod hiv 1-, hiv 2- og HBV-virus. 
Tenofovir has activity against HIV-1, HIV-2, and HBV.
• lægemidler, der anvendes til at behandle sukkersyge: 
• medicines used to treat diabetes:
Tilsvarende steady-state gennemsnitlige værdier for hhv. Cmax, AUCtau og Ctrough (gennemsnit ± SD) var 1,1 ± 0,40 µg/ml, 8,3 ± 3,8 µg•t/ml og 0,05 ± 0,13 µg/ml for cobicistat; 1,9 ± 0,5 µg/ml, 13 ± 4,5 µg•t/ml og 0,14 ± 0,25 µg/ml for emtricitabin. 
Corresponding steady-state mean Cmax, AUCtau, and Ctrough (mean ± SD) were 1.1 ± 0.40 µg/mL, 8.3 ± 3.8 µg•h/mL, and 0.05 ± 0.13 µg/mL for cobicistat; 1.9 ± 0.5 µg/mL, 13 ± 4.5 µg•h/mL, and 0.14 ± 0.25 µg/mL for emtricitabine.
Genvoya bør ikke administreres sammen med andre antiretrovirale lægemidler (se pkt. 
Genvoya should not be co-administered with other antiretroviral medicinal products (see section 4.5).
Samtidig administration af Genvoya og lægemidler, som inducerer CYP3A kan føre til reducerede plasmakoncentrationer af elvitegravir og nedsat terapeutisk virkning af Genvoya (se ”Samtidig brug kontraindiceret” og pkt. 
Co-administration of Genvoya with medicinal products that induce CYP3A may result in decreased plasma concentrations of elvitegravir and reduced therapeutic effect of Genvoya (see “Concomitant use contraindicated” and section 4.3).
Samtidig administration af carbamazepin, en kraftig CYP3A-inducer, kan reducere plasmakoncentrationerne af cobicitat signifikant. 
Co-administration of carbamazepine, a potent CYP3A inducer, may significantly decrease cobicistat plasma concentrations.
Patienterne i kohorte 2 havde en gennemsnitsalder på 10 år (interval: 8 til 11), en gennemsnitlig baselinevægt på 32 kg (interval: 26 til 58), 39 % var mænd, 13 % asiatere, 78 % sorte. 
Patients in Cohort 2 had a mean age of 10 years (range: 8 to 11), a mean baseline weight of 32 kg (range: 26 to 58), were 39% male, 13% Asian, and 78% Black.
Selektive serotoningenoptagshæmmere (SSRI'er, selective serotonine reuptake inhibitors) 
Selective serotonin reuptake inhibitors (SSRIs) Escitalopram
Den gennemsnitlige stigning i CD4+-celletal fra baseline var 230 celler/mm3 hos patienter i Genvoyagruppen og 211 celler/mm3 hos patienter i E/C/F/TDF-gruppen (p = 0,024) ved uge 48 og 326 celler/mm3 i Genvoya-gruppen og 305 celler/mm3 i E/C/F/TDF-gruppen (p = 0,06) ved uge 144. 
The mean increase from baseline in CD4+ cell count was 230 cells/mm3 in Genvoya-treated patients and 211 cells/mm3 in E/C/F/TDF-treated patients (p = 0.024) at Week 48, and 326 cells/mm3 in Genvoya-treated patients and 305 cells/mm3 in E/C/F/TDF-treated patients (p = 0.06) at Week 144.
• elvitegravir, et antiretroviralt lægemiddel, der kaldes en integrasehæmmer 
• elvitegravir, an antiretroviral medicine known as an integrase inhibitor
Tabel 5: Farmakokinetik for elvitegravir, cobicistat, emtricitabin, tenofovir og tenofoviralafenamid hos antiretroviral-naive unge og voksne 
Table 5: Pharmacokinetics of elvitegravir, cobicistat, emtricitabine, tenofovir, and tenofovir alafenamide in antiretroviral-naïve adolescents and adults
Der identificeredes ingen nye sikkerhedsproblemer hos patienter med nyresygdom i slutstadiet i kronisk hæmodialyse, som fik Genvoya (se pkt. 
There were no new safety issues identified in patients with end stage renal disease on chronic haemodialysis receiving Genvoya (see section 4.8).
 Hvis nogle af bivirkningerne bliver alvorlige, skal De fortælle det til lægen. 
 If any of the side effects get serious tell your doctor.
3,7 % (95 % CI: 0,4 % til 7,0 %, p < 0,017c) 
3.7% (95% CI: 0.4% to 7.0%, p < 0.017c)
Koncentrationer af disse HMG Co-A-reduktasehæmmere forventes at øges forbigående ved administration af elvitegravir og cobicistat. 
Concentrations of these HMG Co-A reductase inhibitors are expected to transiently increase when administered with elvitegravir and cobicistat.
Studier af tenofoviralafenamid fra dyr har ikke vist evidens for skadelige virkninger af tenofoviralafenamid på fertilitetsparametre, graviditet eller føtal udvikling (se pkt. 
Studies of tenofovir alafenamide in animals have shown no evidence of harmful effects of tenofovir alafenamide on fertility parameters, pregnancy, or foetal development (see section 5.3).
Den gennemsnitlige plasma hiv 1-rna ved baseline var 4,5 log10 kopier/ml (interval 1,3-7,0), og 23 % havde viral load ved baseline på > 100.000 kopier/ml. 
The mean baseline plasma HIV-1 RNA was 4.5 log10 copies/mL (range 1.3-7.0) and 23% had baseline viral loads > 100,000 copies/mL.
Magnesium/aluminium-indeholdende antacidum-suspension (20 ml enkeltdosis)/Elvitegravir (50 mg enkeltdosis)/Ritonavir (100 mg enkeltdosis) 
Magnesium/aluminium-containing antacid suspension (20 mL single dose)/ Elvitegravir (50 mg single dose)/ Ritonavir (100 mg single dose)
Steady-state gennemsnitlige værdier for hhv. Cmax, AUCtau og Ctrough (gennemsnit ± SD) hos hiv 1-inficerede patienter var 1,7 ± 0,39 µg/ml, 23 ± 7,5 µg•t/ml og 0,45 ± 0,26 µg/ml for elvitegravir, hvilket giver en hæmningskvotient på ~ 10 (forholdet mellem Ctrough: proteinbindingsjusteret IC95 for vildtype hiv 1-virus). 
The steady-state mean Cmax, AUCtau, and Ctrough (mean ± SD) in HIV-1 infected patients, respectively, were 1.7 ± 0.39 µg/mL, 23 ± 7.5 µg•h/mL, and 0.45 ± 0.26 µg/mL for elvitegravir, which provides inhibitory quotient of ~10 (ratio of Ctrough: protein binding-adjusted IC95 for wild-type HIV-1 virus).
Genvoya bør ikke indgives samtidigt med lægemidler, som indeholder tenofoviralafenamid, tenofovirdisoproxil, lamivudin eller adefovirdipivoxil, og som anvendes til behandling af HBV-infektion. 
Genvoya should not be administered concomitantly with medicinal products containing tenofovir alafenamide, tenofovir disoproxil, lamivudine or adefovir dipivoxil used for the treatment of HBV infection.
Eksponeringer for elvitegravir, cobicistat, emtricitabin, tenofovir og tenofoviralafenamid, der blev opnået hos 24 unge patienter i alderen 12 til < 18 år, som fik Genvoya i studie GS-US-292-0106, var sammenlignelig med eksponeringer opnået hos behandlingsnaive voksne efter administration af Genvoya (tabel 5). 
Exposures of elvitegravir, cobicistat, emtricitabine, tenofovir, and tenofovir alafenamide achieved in 24 adolescent patients aged 12 to < 18 years who received Genvoya in Study GS-US-292-0106 were similar to exposures achieved in treatment-naïve adults following administration of Genvoya (Table 5).
Klinisk overvågning af terapeutiske virkninger og bivirkninger anbefales ved samtidig administration af disse lægemidler og Genvoya. 
Clinical monitoring of therapeutic effects and adverse reactions is recommended when these medicinal products are concomitantly administered with Genvoya.
• naturlægemiddel: perikon (Hypericum perforatum) 
• herbal products: St. John's wort (Hypericum perforatum)
Kvindelige patienter i den fertile alder skal enten anvende hormonale antikonceptiva, der indeholder mindst 30 µg ethinylestradiol samt drospirenon eller norgestimat som progestogen, eller anvende anden sikker kontraceptionsmetode (se pkt. 
Female patients of childbearing potential should use either a hormonal contraceptive containing at least 30 µg ethinyloestradiol and containing drospirenone or norgestimate as the progestogen or should use an alternative reliable method of contraception (see sections 4.5 and 4.6).
Genvoya 150 mg/150 mg/200 mg/10 mg filmovertrukne tabletter. 
Genvoya 150 mg/150 mg/200 mg/10 mg film-coated tablets.
Der blev ikke observeret klinisk relevante ændringer i farmakokinetikken for tenofoviralafenamid eller dets metabolit tenofovir hos patienter med let eller moderat nedsat leverfunktion. 
Clinically relevant changes in the pharmacokinetics of tenofovir alafenamide or its metabolite tenofovir were not observed in patients with mild or moderate hepatic impairment.
Klinisk overvågning anbefales og en dosisreduktion kan være nødvendig ved samtidig administration af disse stoffer og Genvoya. 
Clinical monitoring is recommended and a dose decrease may be necessary when these agents are co-administered with Genvoya.
Når De snart ikke har mere af Genvoya, skal De bede om mere fra lægen eller på apoteket. 
When your supply of Genvoya starts to run low, get more from your doctor or pharmacist.
Genvoya bør seponeres hos patienter, hvis den estimerede CrCl falder til under 30 ml/min under behandlingen (se pkt. 
Genvoya should be discontinued in patients with estimated CrCl that declines below 30 mL/min during treatment (see section 5.2).
Emtricitabin er en nukleosid-revers transkriptasehæmmer (NRTI, nucleoside reverse transcriptase inhibitor) og nukleosidanalog af 2'-deoxycytidin. 
Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) and nucleoside analogue of 2'-deoxycytidine.
Efter skift til Genvoya forblev 100 % (23/23) af patienter i kohorte 2 supprimerede (hiv 1-rna < 50 kopier/ml) ved 48 uger. 
After switching to Genvoya, 100% (23/23) of patients in Cohort 2 remained suppressed (HIV-1 RNA < 50 copies/mL) at Week 48.
Hiv 1-inficerede, virologisk supprimerede patienter I studie GS-US-292-0109 blev virkningen og sikkerheden ved skift fra enten efavirenz (EFV)/emtricitabin (FTC)/tenofovirdisoproxil, FTC/tenofovirdisoproxil plus atazanavir (boosted med enten cobicistat eller ritonavir), eller E/C/F/TDF til Genvoya evalueret i et randomiseret, ublindet studie af virologisk supprimerede (hiv 1-rna < 50 kopier/ml) hiv 1-inficerede voksne (n = 1.436). 
In Study GS-US-292-0109, the efficacy and safety of switching from either efavirenz (EFV)/emtricitabine (FTC)/tenofovir disoproxil, FTC/tenofovir disoproxil plus atazanavir (boosted by either cobicistat or ritonavir), or E/C/F/TDF to Genvoya were evaluated in a randomised, open-label study of virologically suppressed (HIV-1 RNA < 50 copies/mL) HIV-1 infected adults (n = 1,436).
Samtidig administration af Genvoya og nogle lægemidler, der primært metaboliseres af CYP3A, kan føre til øgede plasmakoncentrationer af disse præparater, hvilket er forbundet med risikoen for alvorlige eller livstruende bivirkninger, såsom perifer vasospasme eller iskæmi (f.eks. dihydroergotamin, ergotamin, ergometrin) eller myopati, herunder rhabdomyolyse (f.eks. simvastatin, 
Co-administration of Genvoya and some medicinal products that are primarily metabolised by CYP3A may result in increased plasma concentrations of these products, which are associated with the potential for serious or life-threatening adverse reactions such as peripheral vasospasm or ischaemia (e.g., dihydroergotamine, ergotamine, ergometrine), or myopathy, including rhabdomyolysis (e.g., simvastatin, lovastatin), or prolonged or increased sedation or respiratory depression (e.g., orally administered midazolam or triazolam).
I et klinisk studie (GS-US-292-0106), hvor Genvoya blev administreret til 23 hiv 1-inficerede pædiatriske patienter med en gennemsnitsalder på 10 år (interval 8 til 11 år), var gennemsnitseksponeringerne af elvitegravir, cobicistat, emtricitabin, tenofovir og tenofoviralafenamid højere (20 til 80 %) end gennemsnitseksponeringerne hos voksne (se pkt. 
In a clinical study (GS-US-292-0106) in which Genvoya was administered to 23 HIV-1 infected paediatric patients with a mean age of 10 years (range 8 to 11 years), the mean exposures of elvitegravir, cobicistat, emtricitabine, tenofovir, and tenofovir alafenamide were higher (20 to 80%) than the mean exposures achieved in adults (see sections 4.1 and 5.2).
Samtidig administration af Genvoya kan føre til nedsat eksponering over for elvitegravir og/eller cobicistat og svigtende terapeutisk virkning samt udvikling af resistens. 
Co-administration with Genvoya may lead to decreased elvitegravir and/or cobicistat exposures and loss of therapeutic effect and development of resistance.
I dyrestudier var der ingen virkning af elvitegravir, cobicistat, emtricitabin og tenofoviralafenamid på parrings- eller fertilitetsparametre (se pkt. 
In animal studies there were no effects of elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide on mating or fertility parameters (see section 5.3).
Tabel 6: Farmakokinetik for elvitegravir, cobicistat, emtricitabin, tenofovir og tenofoviralafenamid hos virologisk supprimerede børn og voksne 
Table 6: Pharmacokinetics of elvitegravir, cobicistat, emtricitabine, tenofovir, and tenofovir alafenamide in virologically suppressed children and adults
Gennemsnitsalderen var 36 år (interval 18-76), 85 % var mænd, 57 % var hvide, 25 % var sorte, og 10 % var asiater. 
The mean age was 36 years (range 18-76), 85% were male, 57% were White, 25% were Black, and 10% were Asian.
I kliniske studier var forekomsten af alvorlige bivirkninger relateret til selvmord 0,6 % (26/4137 forsøgspersoner) for Genvoya. 
In clinical trials, the incidence of SAEs related to suicide for Genvoya was 0.6% (26/4137 subjects), therefore, the frequency proposed is “uncommon”.
Genvoya kan påvirke eller påvirkes af anden medicin. 
Genvoya may interact with other medicines.
Der bør udvises forsigtighed ved samtidig administration af Genvoya og pitavastatin. 
Caution should be exercised when co-administering Genvoya with pitavastatin.
Sikkerheden af Genvoya blev evalueret til og med 48 uger hos hiv 1-inficerede, unge patienter i alderen 12 til < 18 år, der vejede ≥ 35 kg, som enten var behandlingsnaive (GS-US-292-0106, n = 50), eller virologisk supprimerede (GS-US-292-1515, n = 50), og hos virologisk supprimerede børn i alderen 8 til < 12 år, der vejede > 25 kg (GS-US-292-0106, n = 23). 
The safety of Genvoya was evaluated through 48 weeks in HIV-1 infected adolescent patients between the ages of 12 to < 18 years weighing ≥ 35 kg, who were either treatment-naïve (GS-US-292-0106, n = 50), or who were virologically suppressed (GS-US-292-1515, n = 50), and in virologically suppressed children between the ages of 8 to < 12 years weighing > 25 kg (GS-US-292-0106, n = 23).
Hiv 1-inficerede patienter med let til moderat nedsat nyrefunktion I studie GS-US-292-0112 blev virkning og sikkerhed af Genvoya evalueret i et ublindet klinisk studie af 242 hiv 1-inficerede patienter med let til moderat nedsat nyrefunktion (eGFRCG: 30-69 ml/min). 
HIV-1 infected patients with mild to moderate renal impairment In Study GS-US-292-0112, the efficacy and safety of Genvoya were evaluated in an open-label clinical study of 242 HIV-1 infected patients with mild to moderate renal impairment (eGFRCG: 30-69 mL/min).
Der blev ikke observeret nogen klinisk relevante forskelle i farmakokinetikken for elvitegravir, cobicistat, tenofoviralafenamid eller tenofovir hos raske personer og hos patienter med svært nedsat nyrefunktion (estimeret CrCl ≥ 15 ml/min og < 30 ml/min) i fase 1-studier af hhv. cobicistat-boosted elvitegravir og tenofoviralafenamid. 
No clinically relevant differences in elvitegravir, cobicistat, tenofovir alafenamide, or tenofovir pharmacokinetics were observed between healthy subjects and patients with severe renal impairment (estimated CrCl ≥ 15 mL/min and < 30 mL/min) in Phase 1 studies of cobicistat-boosted elvitegravir or of tenofovir alafenamide, respectively.
Plasmakoncentrationer af drospirenon kan øges ved samtidig administration med produkter indeholdende cobicistat. 
Plasma concentrations of drospirenone may be increased when co-administered with cobicistat-containing products.
Aktive stoffer: elvitegravir, cobicistat, emtricitabin og tenofoviralafenamid. 
The active substances are elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide.
Patienterne havde en gennemsnitlig alder på 41 år (interval 21-77), 89 % var mænd, 67 % var hvide og 19 % var sorte. 
Patients had a mean age of 41 years (range 21-77), 89% were male, 67% were White, and 19% were Black.
Samtidig administration af Genvoya og nogle lægemidler, som inducerer CYP3A såsom perikon (Hypericum perforatum), rifampicin, carbamazepin, phenobarbital og phenytoin kan føre til signifikant reducerede plasmakoncentrationer af cobicistat og elvitegravir, hvilket kan forårsage svigtende terapeutisk virkning og udvikling af resistens (se pkt. 
Co-administration of Genvoya and some medicinal products that induce CYP3A such as St. John's wort (Hypericum perforatum), rifampicin, carbamazepine, phenobarbital, and phenytoin may result in significantly decreased cobicistat and elvitegravir plasma concentrations, which may result in loss of therapeutic effect and development of resistance (see section 4.3).
Studier af reproduktionstoksicitet udført hos rotter og kaniner med cobicistat viste ingen virkninger hverken på parrings-, fertilitets-, graviditets- eller fosterparametre. 
Reproductive toxicity studies in rats and rabbits with cobicistat showed no effects on mating, fertility, pregnancy or foetal parameters.
Tabel 2: Bivirkninger i tabelform Hyppighed 
Table 2: Tabulated list of adverse reactions
Det er ukendt, om elvitegravir, cobicistat eller tenofoviralafenamid udskilles i human mælk. 
It is not known whether elvitegravir, cobicistat, or tenofovir alafenamide are excreted in human milk.
Det er påvist, at behandling med cobicistat og elvitegravir i andet og tredje trimester af graviditeten medfører lavere eksponering for elvitegravir (se pkt. 
Treatment with cobicistat and elvitegravir during the second and third trimesters of pregnancy has been shown to result in lower elvitegravir exposure (see section 5.2).
76 % af patienterne var mænd, 82 % var sorte og 18 % var hvide. 
Seventy-six percent were male, 82% were Black and 18% were White.
I hiv 1-isolaterne fra 12 patienter med resistensudvikling i E/C/F/TDFgruppen var de mutationer, der opstod, M184V/I (n = 9), K65R/N (n = 4) og L210W (n = 1) i RT og E92Q/V (n = 4) og Q148R (n = 2) og N155H/S (n = 3) i integrase. 
Of the HIV-1 isolates from 12 patients with resistance development in the E/C/F/TDF group, the mutations that emerged were M184V/I (n = 9), K65R/N (n = 4), and L210W (n = 1) in RT and E92Q/V (n = 4), and Q148R (n = 2), and N155H/S (n = 3) in integrase.
Sikkerheden af Genvoya hos 248 hiv 1-inficerede patienter, der enten var behandlingsnaive (n = 6) eller virologisk supprimerede (n = 242) med let til moderat nedsat nyrefunktion (estimeret glomerulær filtrationshastighed via Cockcroft-Gault-metoden [eGFRCG]: 30-69 ml/min) blev evalueret til og med 144 uger i et ublindet klinisk studie (GS-US-292-0112). 
The safety of Genvoya in 248 HIV-1 infected patients who were either treatment-naïve (n = 6) or virologically suppressed (n = 242) with mild to moderate renal impairment (estimated glomerular filtration rate by Cockcroft-Gault method [eGFRCG]: 30-69 mL/min) was evaluated through 144 weeks in an open-label clinical study (GS-US-292-0112).
samtidig administration af Genvoya 
Recommendation concerning co-administration with Genvoya
Samtidig administration af Genvoya kan føre til øgede plasmakoncentrationer af dabigatran med lignende virkninger som ved andre kraftige hæmmere af P-gp. 
Co-administration with Genvoya may increase dabigatran plasma concentrations with similar effects as seen with other strong P-gp inhibitors.
Dosismodifikationer er ikke nødvendige ved samtidig administration af rosuvastatin og Genvoya. 
Dose modifications are not necessary when rosuvastatin is administered in combination with Genvoya.
Steady-state gennemsnitlige værdier for Cmax og AUCtau for tenofoviralafenamid var hhv. 0,16 ± 0,08 µg/ml og 0,21 ± 0,15 µg•t/ml for tenofovir. 
Steady-state mean Cmax and AUCtau for tenofovir alafenamide were 0.16 ± 0.08 µg/mL and 0.21 ± 0.15 µg•h/mL, respectively.
Koncentrationer af warfarin kan påvirkes ved samtidig administration af Genvoya. 
Concentrations of warfarin may be affected upon co-administration with Genvoya.
Den antivirale aktivitet af tenofoviralafenamid mod isolater af hiv 1 undertype B fra laboratoriet og klinikken blev vurderet i lymfoblastoide cellelinjer, PBMC'er, primære monocyt-/makrofage celler og CD4+ T-lymfocytter. 
The antiviral activity of tenofovir alafenamide against laboratory and clinical isolates of HIV-1 subtype B was assessed in lymphoblastoid cell lines, PBMCs, primary monocyte/macrophage cells and CD4+-T lymphocytes.
Det gennemsnitlige CD4+ celletal ved baseline var 545 celler/mm3 (interval: 205-1473). 
The mean baseline CD4+ cell count was 545 cells/mm3 (range 205-1473).
Mitokondriel dysfunktion bør overvejes hos alle børn med svære kliniske symptomer af ukendt ætiologi, især neurologiske symptomer, der har været eksponeret for nukleosid-/nukleotidanaloger in utero. 
These findings should be considered for any child exposed in utero to nucleos(t)ide analogues, who present with severe clinical findings of unknown aetiology, particularly neurologic findings.
Der foreligger utilstrækkelige data for virkningen af elvitegravir, cobicistat, emtricitabin og tenofovir på det ammede barn. 
There is insufficient information on the effects of elvitegravir, cobicistat, emtricitabine and tenofovir in newborns/infants.
Gennemsnitseksponeringer for elvitegravir, cobicistat, emtricitabin, tenofovir og tenofoviralafenamid, der blev opnået hos børn i alderen 8 til < 12 år (> 25 kg; n = 23), som fik Genvoya i studie GS-US-292-0106, var højere (20 til 80 %) end gennemsnitseksponeringer hos voksne (Tabel 6). 
Mean exposures of elvitegravir, cobicistat, emtricitabine, tenofovir, and tenofovir alafenamide achieved in children aged 8 to < 12 years (> 25 kg; n = 23) who received Genvoya in study GS-US-292-0106 were higher (20 to 80%) than the mean exposures achieved in adults (Table 6).
Ved baseline var gennemsnitligt hiv 1-rna i plasma 4,6 log10 kopier/ml, median CD4+ celletal var 456 celler/mm3 (interval: 95 til 1.110), og median CD4+ % var 23 % (interval: 7 til 45 %). 
At baseline, mean plasma HIV-1 RNA was 4.6 log10 copies/mL, median CD4+ cell count was 456 cells/mm3 (range: 95 to 1,110), and median CD4+% was 23% (range: 7 to 45%).
Emtricitabin viste antiviral aktivitet i cellekultur mod hiv 1-kladerne A, B, C, D, E, F og G (EC50-værdier var i intervallet fra 0,007 til 0,075 µM) og viste stammespecifik aktivitet mod hiv 2 (EC50-værdier var i intervallet fra 0,007 til 1,5 µM). 
Emtricitabine displayed antiviral activity in cell culture against HIV-1 clades A, B, C, D, E, F, and G (EC50 values ranged from 0.007 to 0.075 µM) and showed strain specific activity against HIV-2 (EC50 values ranged from 0.007 to 1.5 µM).
Kør ikke motorkøretøj, lad være med at cykle og lad være med at arbejde med værktøj eller maskiner, hvis De bliver svimmel, når De tager Genvoya. 
If you feel dizzy when taking Genvoya, do not drive or ride a bicycle and do not use any tools or machines.
Efter oral administration af [14C]-elvitegravir/ritonavir blev 94,8 % af dosis genfundet i fæces i overensstemmelse med den hepatobiliære udskillelse af elvitegravir. 
Following oral administration of [14C]-elvitegravir/ritonavir, 94.8% of the dose was recovered in faeces, consistent with the hepatobiliary excretion of elvitegravir; 6.7% of the administered dose was recovered in urine.
Sikkerheden af Genvoya hos 55 virologisk supprimerede hiv 1-inficerede patienter med nyresygdom i slutstadie (eGFRCG < 15 ml/min) i kronisk hæmodialyse blev evalueret til og med 48 uger i et ublindet klinisk studie med én behandlingsarm (GS-US-292-1825). 
The safety of Genvoya in 55 virologically suppressed HIV-1 infected patients with end stage renal disease (eGFRCG < 15 mL/min) on chronic haemodialysis was evaluated through 48 weeks in a single arm, open-label clinical study (GS-US-292-1825).
Koncentrationer af voriconazol kan øges eller reduceres ved samtidig administration af Genvoya. 
Concentrations of voriconazole may increase or decrease when co-administered with Genvoya.